Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC
Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces that it has closed an 87 million series A financing round.
- Emergence Therapeutics AG, a biopharmaceutical company developing novel antibody drug conjugates (ADC) for the treatment of cancers with high unmet needs, today announces that it has closed an 87 million series A financing round.
- Proceeds from this funding round will be used to advance the companys next-generation antibody drug conjugate (ADC) targeting Nectin-4 to clinical proof-of-concept as well as the development of additional ADC programs.
- Emergences lead asset, ETx-22, is a next-generation Nectin-4 ADC which has been optimized to increase efficacy and minimize toxicity.
- Jack Elands, CEO of Emergence Therapeutics, commented: The completion of this significantly oversubscribed round enables Emergence to execute on its strategy to become a dominant ADC developer.